Drugs / LKA651
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02867735 | Sep 2016 → Feb 2018 | diabetic macular edema, macular retinal edema, retinal vein occlusion, wet macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02281292 | Dec 2015 → Jun 2017 | diabetic macular edema | Alcon Research | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03927690 | May 2019 → Jun 2022 | diabetic macular edema | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LKA651 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03927690 ↗ |
| Route | Intravitreal | “administered as a single IVT injection in the study eye” NCT02281292 ↗ |